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Abstract
We report on a 5-year old girl from Mbanza-Ngungu (formerly Thysville), a Congolese rural
city, who developed atopic eczema skin lesions during infancy and which, later on, became
recalcitrant despite a long period treatment with some steroid preparations, zinc oxide and also
local ethnomedicine products. She was first diagnosed with psoriasis by the first doctor 4 years
before. At the admission, she presented with severe lichenification, oozing, swelling and
hyperpigmention on large areas of upper and lower limbs and trunk. Her skin condition has
seriously affected her quality of life and she had an associated Tinea capitis. After a careful
history taking, physical examination and use of the Haniffin and Rajka AD diagnostic criteria
while considering the localization of sk in lesions, the diagnosis of severe and recalcitrant
atopic eczema was considered. She was treated with a twice daily application of 10% Vernonia
amygdalina extracts, an African edible plant that exerts anti-itch and antiallergic activities.
And Tinea capitis was successfully treated with 3 week topical 2% Miconazole. A marked
improvement of eczema area severity index (EASI) and dermatological life quality index
(DLQI) was noted 3 weeks later, with reduction of total serum IgE, eosinophilia and erythrocytes
sedimentation ra te (ESR) at day40 of treatment. An improvement of the country’s health
system and provision of specialized health care in the rural areas could help  to prevent
misdiagnosis of treatable diseases in poor settings.
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1.  Introduction
Atopic dermatitis (AD) is an itchy, inflammatory skin condition
with a predilection for skin flexures. In the chronic stage, the disease
is characterized by erythema, edema, vesicles and weeping and
skin lichenification or thickening (Williams, 2005; Aoki et al., 1992).
AD is a complex disease that relies on the interplay of several
factors; and, both environmental (allergens and other triggers)
determinants and genetic factors are reported to play an important
role in the disease onset and aggravation, and 15-20% of children
are affected in developed countries (Nemoto-Hasebe et al., 2009;
Olesen et al., 2003; Scharschmidt et al., 2009).
A 5-year-old girl from the rural city of Mbanza-Ngungu (formerly
Thysville), Bas-Congo province, Democratic Republic of Congo,
has been suffering from AD since infancy, nearly before reaching
her second year of life. According to her mother, the child first
presented with redness of the skin and papulous lesions on upper
limbs; she also revealed that one of her relative often suffers from
skin allergy. Later on, similar skin lesions developed on lower limbs,
progressively extending to the trunk as the patient grew older, and
she was often scratching.
At the first local medical setting she visited, the mother was told
by the doctor that her daughter had psoriasis. Thereafter, she had
to see different doctors; however, there was still no improvement
of the child’s condition. Topical steroids (including betamethasone)
and zinc oxide were among the drugs prescribed. Since 2009, her
parents have been seeing traditional practitioners and healers, as
the medications from hospitals did not improve the patient’s
condition. However, her condition worsened with extended








2.  Materials and Methods
2.1  Physical examination and diagnosis
From November 2010 through April 2011, our Congolese-Japanese
collaborative research team conducted a dermatological screening,
followed by a preliminary clinical trial that consisted on providing
healthcare for allergic skin diseases in Bas-Congo province,
Democratic Republic of Congo, to patients with mild to moderate
conditions. Miss B, a 5-year old girl, was accompanied by her
mother to one of our study sites. She was taken care by our team
but was not recruited in the study because of the severity of her
condition and also she had an associated fungal skin disease.
The history of her disease goes back to the time she was nearly 2
years old. Her parents have visited different medical settings as
mentioned above. They also visited traditional practitioners and
healers who have been using different plant materials as remedy;
however, the kid’s condition was getting worse. At the admission,
she presented with oozing, lichenification squamous lesions,
swelling of skin, scratch markings, and hyperpigmentation of skin
on the antecubital fossae, legs and back (Figure 1A) she also had
difficulty to walk due to thickened and painful lesions on her knees.
The girl was wearing clothing that covered almost her entire body
and was avoiding playing with friends. In addition, the patient had
mycotic skin lesions on her head. After a careful history taking and
physical examination, and considering the Haniffin and Rajka’s AD
diagnostic criteria and the distribution of skin lesions (limbs, trunk
and back), we concluded that she had a severe, chronic and
recalcitrant atopic dermatitis associated with Tinea capitis
(a common fungal skin infection in Congolese rural children). The
disease (AD) severity was evaluated using the ‘eczema area and
severity index’ (EASI) scoring system, as previously reported
(Hanifin et al., 2001), considering the severity of each skin symptom
(redness, thickness, scratching and lichenification: 0, absence; 1,
mild; 2, moderate; 3, severe) localized on neck/head, trunk, upper
and lower limbs; in addition, a patient self-evaluation of
dermatology quality of life index (DQLI) (Chen, 2007) was
performed once a week by interviewing the mother.
2.2  Hematologic, immunologic assays and mycological culture
Blood sample was drawn on day1 and 6 weeks later (day40) for
biological and immunological (total IgG, IgE), hepatic function
(alanine aminotransferase, ALT; aspartate transaminase, AST)
assays. White blood cells count and erythrocytes sedimentation
rate (ESR) assays were performed at a local health center (Noki
hospital, Bas-Congo province), whereas immunologic and hepatic
function markers were assayed at a specialized laboratory (Lomo
Medical laboratory, Kinshasa, Congo DR). Potassium hydroxide
(KOH) microscopy was positive and mycological culture
(Sabouraud’ dextrose agar; Saruta clinic of dermatology, Japan) of
collected scalp samples isolated Trichophyton canis.
2.3  Treatment
As the patient has a history of an unsuccessful betamethasone and
dexamethasone treatment-the only drugs available in this resource
limited rural area-she was treated, twice daily, with topical
application of 10% Vernonia amygdalina extracts (Vamex)  (African
edible plant with antiallergic properties) ointment. Tinea capitis
was successfully cured after a three-week topical 2% miconazole
treatment. No other medication was added until completion the 8-
week treatment period.
2.4  Ethical consideration
The ethics committee of Kochi Medical School approved the study
protocol of the clinical study (Ethics committee No 22-59) and a
written approval from the provincial medical authority was
obtained. Regarding patient B, a verbal informed consent was
obtained from the child’s mother, an illiterate farmer.
3.  Results and Discussion
A marked improvement was noted for lesions on upper and lower limbs,
neck and trunk and back (Figure 1B) with an improvement of the disease
severity (EASI score: 38.4 vs. 6.2 at day1 and day40, respectively) and
life quality (DLQI: 16 vs. 34; respectively). She was no more scratching
and could walk and even run. Results from the hematologic and immunologic
assays were as follows (Figure 2):
(a) Leukocytes: eosinophils: 5 vs. 2%, basophils: 2 vs. 0%,
lymphocytes: 32 vs.27%; monocytes: 6 vs. 3%; neutrophils:
61 vs. 53 on day1 and day40, respectively;
(b) ESR: 51 mm/h vs. 32 mm/h, respectively;
(c) WBC: 11,200 vs. 9,700/ mm³, respectively;
(d) Total IgG: 42 IU/L vs. 38 IU/L, respectively;
(e) Serum total IgE: 0.023 vs. 0.002 IU/L, respectively;
(f) Serum ALT: 26 IU/L vs. 24 IU/L; serum AST: 17 vs. 19 IU/L,
respectively.
No adverse effect was neither observed by the clinician nor reported
by the patient or her parent during the course of treatment.
After a long period of discomfort due severe skin lesions, our
patient’s condition could improve following the use of topical
Vernonia amygdalina extracts. This amelioration of the severity of
the disease might be related to:
 the decrease in serum total IgE level; this immunoglobulin is
associated with the development of AD in most cases through
upregulation of inflammatory allergic inflammation-dependent
Th-2 cytokines production (Rybojad,2012; Tanei, 2012);
 the potent anti-inflammatory activity of its bioactive flavonoids
(Quercetin, Luteolin, Dicafeoylquinic acid) and terpenoids such
as Vernodalinol, from Vernonia amygdalina leaf, which exert
an inhibitory effect of ERK/MAPK pathways. Those
chemicals are reported to confer to the plant its anti-
inflammatory and anticancer properties (Oyugi et al., 2009;
Toyang and Verpoorte, 2013; Luo et al., 2011). Our recent
study demonstrated the antiallergic activity of both water and
alcoholic extracts of the Congolese Vernonia amygdalina in
animals and humans (Ngatu et al., 2012).
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There are some lessons to be considered in this report, which
consists of a patient taken care in an area where specialized
healthcare is particularly rare and more than half of population rely
on traditional practitioners and healers. The misdiagnosis of the
patient’s condition could be due to the limited skills of general
practitioners in the field of skin diseases, and, on the other hand,
the lack of specialist doctors in hospitals located in most rural
cities. Actually, Haniffin and Rajka diagnostic criteria for AD are
used internationally. It is a useful tool in the differential diagnosis
of eczematous and other itch and /or skin barrier defect associated
skin diseases like AD.
The patient condition got worsened possibly due to lack of
adherence to previously prescribed treatments (steroids) rather
than their ineffectiveness, which might have made her condition
recalcitrant. Furthermore, the use of plant materials that had no
proven efficiency by traditional practitioners and healers could
have aggravated skin lesions that we observed at the time of patient’s
admission. Though there were a few dyschromic spots on her lower
limbs remaining after 8 weeks of treatment, our patient’s condition
improved considerably and no adverse effect was noted. An
improvement of the country’s health system and provision of
specialized health care in the rural areas could help prevent
misdiagnosis of treatable diseases in poor settings.
Figure 1A: Affected body areas at day5 (week1) (a) and at day21 (b)
after starting topical treatment with 10% Vamex (Vernonia
amygdalina leaf extracts) in a 5-year old Congolese girl
The Figure shows an improvement of patient’s skin condition with
a marked reduction of lichenification and areas of dyschromia both
on upper and lower limbs, with a re-epithelization of previously
affected body areas after 6 weeks of topical VAM extracts treatment.
Figure 2: White blood cells count, ESR, serum total IgG, IgG1, IgG2
and IgE levels
The Figure shows relatively reduced levels of blood leucocytes (WBC)
(A), ESR (B), total serum IgG, IgG1, IgG2 (C) and IgE(D) after 3
weeks of topical treatment with Vernonia amygdalina leaf extracts
As a conclusion, this report suggests that Vernonia amygdalina
leaf extracts could be beneficial as antiallergic agent in humans.
This finding should be confirmed only after conducting a clinical
trial with large sample of patients.
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